

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: BELL Michael Gregory

Serial No.:

:

Application Date:

US Nat'l Entry Date (if applicable):

For: COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

Docket No.: X-16723

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the foreign patent and /or published application and each non-patent reference for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

/James B. Myers/
James B. Myers
Attorney for Applicants
Registration No. 42,021
Phone: 317-276-0755

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

August 31, 2006

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-16723	Serial No
	First Applicant BELL, Michael Gregory	
	US Nat'l Entry (if applicable)	Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US 6,147,090	11-14-2000	DeNinno, et. al.	
	AB	US 2005/0059810	03-17-2005	Maeda, et. al.	
	AC	US 5932587	08-03-1999	Schmeck, et. al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP 0992496	12-04-2000	Pfizer Products, Inc.		
	BB	JP 2003321472A	11-11-2003	Takeda Chemical Industries LTD.		
	BC	UK 1 515 540	6-28-1978	Maurice Prost		
	BD	WO 05/095395	10-13-2005	Tanable		
	BE	WO 00/17166 A	03-30-2000	Pfizer Products, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; BRN 5584498, 1993, XP 002333708, Abstract, Maurice, et al., "Decahydroquinoline derivatives. VIII. 4-Anilino- and 4-anilidodecahydroquinolines and N-substituted derivatives" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 15(3), 215-22 ODEN: EJMCAS; ISSN: 0009-4374, 1980.	
	CB	Bisgaier et al. <u>J of Lipid Res.</u> 1993, 34 , 1625-1634	

Examiner Signature	/Niloofer Rahmani/	Date Considered	10/21/2008
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.
Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/